Evidence map›Paper›PMID 34450333›Full record

ArticleTransplantation and cellular therapy2021

Outcomes and Utilization Trends of Front-Line Autologous Hematopoietic Cell Transplantation for Mantle Cell Lymphoma.

Peter A Riedell, Mehdi Hamadani, Kwang W Ahn, Carlos Litovich, Guru Subramanian Guru Murthy, Frederick L Locke, Claudio G Brunstein, Reid W Merryman, Patrick J Stiff, Attaphol Pawarode and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation and cellular therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. What is the role of up-front autologous stem cell transplantation in mantle cell lymphoma?Hematology. American Society of Hematology. Education Program · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Hematopoietic cell transplantation for mantle cell lymphoma.International journal of hematology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 1 country.

Peter A RiedellDivision of Hematology and Oncology, University of Chicago Medicine, Chicago, Illinois.
Mehdi HamadaniCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin. Electronic address: mhamadani@mcw.edu.
Kwang W AhnCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin.
Carlos LitovichCenter for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Guru Subramanian Guru MurthyBMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.
Frederick L LockeDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Claudio G BrunsteinDivision of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Reid W MerrymanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Masachusetts.
Patrick J StiffDivision of Hematology-Oncology, Department of Medicine, Loyola University Stritch School of Medicine, Maywood, Illinois.
Attaphol PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan.
Taiga NishihoriDepartment of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, Florida.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, Florida.
Alex F HerreraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
Craig S SauterAdult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medical College, New York, New York.
Sonali M SmithDivision of Hematology and Oncology, University of Chicago Medicine, Chicago, Illinois.
Medical College of Wisconsin · USMoffitt Cancer Center · USUniversity of Chicago · USCity Of Hope National Medical Center · USDana-Farber Cancer Institute · USLoyola University Chicago · USMayo Clinic in Florida · USMemorial Sloan Kettering Cancer Center · USUniversity of Michigan · USUniversity of Minnesota · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
Integrated Exchange and Storage of Current- and Future-Generation Immunogenomic DataR01AI128775 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JILL Allison HOLLENBACH, STEVEN JOHN MACK · 2017 to 2026
$4.5M
Improving the Availability of Younger Unrelated Hematopoietic Stem Cell DonorsR01HL130388 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SWITZER, GALEN E. · 2016 to 2018
$1.3M
NCI NIH HHS P30 CA008748NCI NIH HHS U24 CA076518NHLBI NIH HHS R01 HL130388NHLBI NIH HHS U10 HL069294NIAID NIH HHS R01 AI128775
6 · The paper itself

Abstract

Although autologous hematopoietic cell transplantation (auto-HCT) has become a common practice for eligible patients in the front-line setting with mantle cell lymphoma (MCL), there are limited data regarding trends in auto-HCT utilization and associated outcomes. This study used the Center for International Blood and Marrow Transplant Research (CIBMTR) database to evaluate survival outcomes and auto-HCT utilization in adults age ≥18 years who underwent auto-HCT within 12 months of diagnosis of MCL between January 2000 and December 2018. The 19-year period from 2000 to 2018 was divided into 4 separate intervals-2000 to 2004, 2005 to 2009, 2010 to 2014, and 2015 to 2018-and encompassed 5082 patients. To evaluate transplantation utilization patterns, we combined MCL incidence derived from the SEER 21 database with CIBMTR- reported auto-HCT activity within 12 months of diagnosis of MCL. Primary outcomes included overall survival (OS) along with the auto-HCT utilization rate. The cumulative incidence of nonrelapse mortality at 1 year decreased from 7% in the earliest cohort (2000 to 2004) to 2% in the latest cohort (2015 to 2018). Mirroring this trend, OS outcomes improved continually with time, with a 3-year OS of 72% in the earliest cohort improving to 86% in the latest cohort. In addition, we noted an increase in auto-HCT utilization from 2001 to 2018, particularly in patients age ≤65 years. This large retrospective analysis highlights trends in auto-HCT utilization and outcomes in patients with MCL and emphasizes the need to optimize pretransplantation and post-transplantation treatment strategies to enhance survival outcomes.

Indexed as

Hematopoietic Stem Cell TransplantationLymphoma, Mantle-CellAdolescentAdultAgedHumansRetrospective StudiesTransplantation, AutologousTransplantation ConditioningAutologous transplantationChemoimmunotherapyMantle cell lymphomaTransplantation outcomesTransplantation utilization

Identifiers

PMID34450333
PMCPMC8556305
OpenAlexW3194141756

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.